To BaP or not to BaP? That is the question. by Goldstein, L S
Benzo[a]pyrene (BaP), a polycyclic aromatic hydrocarbon (PAH) and
animal carcinogen, is used by regulators as the basis for quantitative
risk estimation of PAH-containing combustion by-products (1). Is
BaP an appropriate predictor of cancer risk for products of incomplete
combustion? 
A multidose, 2-year (chronic) feeding protocol developed by the
National Institute of Environmental Health Sciences is a study
design for identifying and characterizing chemicals that pose a can-
cer risk. The National Center for Toxicological Research (NCTR)
of the U.S. Food and Drug Administration and EPRI used this pro-
tocol to study tumor outcomes in mice fed BaP and coal tar (2).
Coal tar is a BaP-containing material found in Superfund sites and
in sites once used in the production of manufactured gas. 
Tumor incidence was very different for coal tar and BaP. Coal
tar caused tumors in lung, skin, forestomach, small intestine, and
liver and also caused hemangiosarcomas and histiosarcomas in vari-
ous organs. BaP caused tumors in forestomach, tongue, esophagus,
and larynx. 
In mice fed coal tar, the lung was the most sensitive organ site for
tumor formation. In mice fed BaP, the forestomach was the most
sensitive site for tumor formation. Significantly, BaP did not induce
lung tumors, even though there was evidence that BaP or an active
metabolite of BaP had reached lung tissue (3). Ingested coal tar is a
systemic tumorigen; ingested BaP is a contact tumorigen. 
When an agent causes tumors in more than one site, as is the case
for ingested coal tar and BaP, tumor incidence in the most sensitive
tissue site is used for risk assessment. In the NCTR/EPRI study,
health risks of coal tar would be based on lung tumor incidence and
health risks of BaP would be based on forestomach tumor incidence.
Gaylor et al. (4) concluded that “... carcinogenicity of coal tars cannot
be fully accounted for by BaP content [of coal tar] since BaP alone
did not induce tumors of the lung.”
The findings of the 2-year feeding study are consistent with
other data on the contribution of BaP to lung tumor induction by
environmental PAHs. In 1972 the Committee on Biological
Effects of Atmospheric Pollutants of the National Academy of
Sciences evaluated the relationship of BaP dose and lung cancer
mortality. Based on epidemiologic evidence from urban dwellers,
British gas workers, and topside coke-oven workers, the committee
concluded that a BaP lung cancer mortality ratio relationship
“lacks plausibility” because an increased dose increment of 100-
fold between the urban resident and the British gas worker hardly
increased the cancer mortality ratio. On the basis of implantation
studies in the rat, Grimmer et al. (5) estimate that BaP contributes
between 0.17 and 4% of the lung carcinogenic potency of conden-
sates from diesel and gas engine exhaust, flue gas from residential
furnaces, and sidestream cigarette smoke.
The lack of lung tumorigenicity of
ingested BaP contrasts with the exten-
sive body of information that demon-
strates the efficacy of BaP for inducing skin tumors in mice when
applied directly to skin. The ability to form skin tumors after dermal
application contributes considerably to the weight of evidence
approach used to establish whether a PAH is a suspected human car-
cinogen. However PAH metabolism is different in different organs.
Mouse skin has some metabolizing enzymes in common with mouse
liver, but lacks others (6). For BaP, tumorigenicity in skin following
topical administration does not predict tumorigenicity in lung fol-
lowing ingestion. 
Clearly the route of administration plays a role in tumorigenesis
because BaP induces lung tumors when administered by intraperi-
toneal injection or oral intubation, at least in a susceptible strain of
mice (7,8). For regulatory purposes, laboratory studies using a route
of administration consistent with environmental exposure are pre-
ferred. Thus ingestion, inhalation, or topical administration are pre-
ferred over oral intubation, intratracheal instillation, surgical
implantation, or intraperitoneal injection. 
Determining the cancer risk of any chemical requires knowledge
of its potency. BaP potency is currently calculated from data in two
studies. Neither study was designed or conducted for the purpose of
developing a BaP cancer potency factor, and neither is adequate for
this application. In the first study (9), forestomach tumor incidences
were determined when BaP was fed to mice of different ages for
varying durations, with varying follow-up times and uncertain
pathological evaluations. The preferred protocol is a lifetime expo-
sure in mature rodents using rigorous laboratory procedures includ-
ing the highest quality pathologic evaluation. In the second study
(10), single tumor incidences that individually were not significant
from three different sites (esophagus, larynx, and forestomach) were
combined and evaluated as if they were a single tumor type. The pre-
ferred protocol bases the cancer potency factor on tumor incidence
in the most sensitive individual site. 
Using the data from the NCTR/EPRI study, which incorporated
the preferred rigorous laboratory procedures, Gaylor et al. (11) calcu-
lated a potency factor for BaP of 1.2/mg/kg/day. This is only one-
sixth the value reported in the Integrated Risk Information System
(IRIS) of the U.S. Environmental Protection Agency (U.S. EPA) and
derived from the less-than-adequate studies. Because the potency fac-
tors for other PAHs in IRIS rely on the potency factor for BaP, any
change in the BaP potency factor would change the potency factors
for all other PAHs. 
Environmental PAHs are always found as complex mixtures, but
most laboratory studies are conducted using a single chemical.
Results from studies with a single agent may not predict results when
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risk of environmental PAHs on the basis of new information.that agent is part of a mixture of other chemicals. BaP in the pres-
ence of other PAHs in a mixture formulated to approximate their
relative abundance in an environmental coal tar (12) did not induce
tumors, whereas BaP by itself did (13). One interpretation is that the
other PAHs reduced the tumorigenic effectiveness of BaP. If this is
generally true, the actual potency of BaP in environmental PAHs
may be much less than the potency determined in studies of BaP
alone. Regulatory determinations based currently on the IRIS BaP
potency may be too conservative. 
Taken together, these data strongly suggest that a regulatory
scheme based on BaP to estimate the risk posed by coal tars and
other environmental PAHs is inconsistent with the role of BaP in
human lung cancers, the health outcome upon which regulation
should be based. Yet there is a need to address and correct the
potential human health risk posed by PAH-contaminated sites. Are
there alternatives to BaP for estimating risks of PAHs? 
One approach considers an environmental PAH such as coal tar
as if it were a single chemical. This method is supported by the
analysis of Gaylor et al. (11), who found that estimates of potency
for lifetime tumor risk at different tissue sites for two different coal
tars in the NCTR/EPRI study varied by a factor of < 2. More data
are needed to ensure that this is true for other coal tars and perhaps
for other environmental PAHs. A shortcoming is that weathered
PAHs in soil tend to differ from native tars in their PAH composi-
tion. Risk could be overestimated or underestimated depending on
whether the carcinogenic factor is enriched or depleted. 
Another approach is to identify a lung tumor-inducing PAH
better suited for risk assessments than BaP. A recent discovery may
point the way. 7H-benzo(c)fluorene is a little-studied PAH that
had not been implicated in cancer outcomes because it did not
induce mouse skin tumors on dermal exposure (14,15). It is gener-
ally accepted that tumor formation by PAHs is associated with the
formation of genetic damage, termed DNA adducts. Now,
researchers have found that 7H-benzo(c)fluorene is likely to be
responsible for significant levels of DNA adducts in the lungs of
mice fed coal tar (16). 7H-benzo(c)fluorene administered by
intraperitoneal injection induces lung tumors in susceptible mice
(17), suggesting a role for 7H-benzo(c)fluorene in coal tar-induced
lung tumors. Studies are currently under way to determine if ingest-
ed 7H-benzo(c)fluorene alone, or in the presence of other PAHs,
induces lung tumors. 
Experimental data indicate that the extensive knowledge scien-
tists and regulators have on carcinogenesis by BaP is of limited value
when estimating the human health risk of environmental PAHs. The
science currently supporting the U.S. EPA’s use of BaP for risk
assessment of PAHs was not designed for that purpose. Because there
are so many sources of environmental PAHs, it is especially impor-
tant that PAH risk be evaluated appropriately and accurately. We
must develop new perspectives and new methods for estimating the
risk of environmental PAHs on the basis of new information. We
must be especially aware of tumor induction following ingestion and
inhalation because these constitute major routes of exposure in
humans. We must appreciate the contributions to human lung
tumor incidence of PAHs that have been neglected because they do
not induce tumors when they are painted on mouse skin. 
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